Navigation Links
Omnicell to Present at Thomas Weisel Healthcare Conference 2007
Date:8/30/2007

MOUNTAIN VIEW, Calif., Aug. 30 /PRNewswire-FirstCall/ -- Omnicell, Inc. (Nasdaq: OMCL) a leading provider of systems and software solutions targeting patient safety and operational efficiency in healthcare facilities, today announced that Randall A. Lipps, chairman, president & CEO and Rob Seim, vice president & CFO will present at the Thomas Weisel Partners Healthcare Conference 2007 at the Four Seasons in Boston, Mass., on Wednesday, September 5, 2007 at 11:30 a.m. Eastern Time.

A live audio-webcast of the presentation may be accessed by visiting the Thomas Weisel Partners Web site at:

http://www.veracast.com/webcasts/twp/healthcare07/07107295.cfm.

Following the conference, a replay of the audio-webcast will also be archived on the site.

About Omnicell

Omnicell, Inc. (Nasdaq: OMCL) is a leading provider of systems and software solutions targeting patient safety and operational efficiency in healthcare facilities. Since 1992, Omnicell has worked to enhance patient safety and allow clinicians to spend more time with their patients.

Omnicell's medication-use product line includes solutions for the central pharmacy, nursing unit, operating room, and patient bedside. Solutions range from large central pharmacy "smart inventory" carousels to small handheld devices. From the point at which a medication arrives at the receiving dock to the time it is adminis
'/>"/>

SOURCE Omnicell, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
2. Researchers Present Ways To Reduce The Risk Of Dementia
3. Researchers Present Data Regarding The Efficiency Of Herbs
4. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
5. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
6. Drug Reactions First Present Themselves In The Mouth
7. Reminiscing Into The Past Makes You Dissatisfied With The Present
8. Living In The Past Indicates Dissatisfaction With Present
9. Movies Represent Coma In A Wrong Way
10. Onchocerciasis: Presentation And Treatment
11. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...re-USNewswire/ -- This release is,being sent in a ... with the,National Cancer Institute, part of the N... American Society of Clinical,Oncology meeting in ...ctice,in about 25 percent of patients with colon c... way colorectal cancers will be staged., * This n...
(Date:5/16/2008)...ers, WASHINGTON, May 16 /PRNewswire-USNewswire/ -...echnicians in the Greater Portland, Oregon and,Van...ever contract as,Teamsters., "The Teamsters are p...ong contract that gives them job protection and a ...President Jim Hoffa., The workers, both full-time...
(Date:5/16/2008)...icenter Phase III clinical trial has found that th...) significantly delays cancer progression in patie...d worsened on other treatments. The study was led...emorial Sloan-Kettering Cancer Center (MSKCC), who... meeting of the American Society for Clinical Onco...
(Date:5/16/2008)... care medicine is in a precipitous decline, David ...ge of Physicians (ACP), today joined with leading...ue a call for comprehensive reforms to attract, re...ary care physicians. , During a panel discussio...., Dr. Dale and other panelists spoke about the ch...
Breaking Medicine News(10 mins):Health News:New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer 2Health News:Drug fends off kidney cancer progression 2Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2
...nd that Invitro Fertilization (IVF) resulted in an...ing to the statistics it is found// that the compl...omen who have IFV. Placenta praevia is the common ...ncy. In this the placenta covers part or the entir...
...ospital bed mourning in agony and pain, as a nurse...rom her body//. Her condition seems to be life th...y frame (a classical sign of malnutrition) was see...doctors treating the girl in the western state of ...
...p of commonly used cholesterol-lowering drugs, use...iomyopathy) due to an anti-arrhythmic effect. Sc...nischemic Cardiomyopathy Treatment Evaluation (def...n cardiac deaths with cardiomyopathy due to a surv...
...ple who have suffered from hardships early in thei...ew study reports// that they in reality become mor...ullible adults; this was the finding of a new stud...scientists found that the people who suffered from...
Other Medicine News:Health News:India's Economic Boom Pack To Waste Children Life 2
(Date:5/15/2008)...ATER, N.J., May 15 /- Sanof...today that findings from the,landmark ATHENA study...py,for the treatment of patients with atrial fibri...ardiovascular hospitalizations or death from any,c...002), meeting the study,primary endpoint. The ATHE...
(Date:5/15/2008)... May 15 /- CenterWatch, a publishing ... research about clinical,trials, finds that invest...electronic data capture) systems. More than 75% of...ted that they had been trained on three or more,ED...the effectiveness of,their EDC training had improv...
(Date:5/15/2008)...vantage Fee-For-Service Plan Positions Blue Cross ...According to a New Report from ...ay 15 /- HealthLeaders-InterStudy, th...ence, reports that as the,economy continues to sta...gan remains the best equipped of all of its compet...
(Date:5/15/2008)...AY, Wis., May 15 /- Omega 3 fatty aci...onsidered as a credible natural,alternative and ma...tients,recent in vivo French study reveals. While...of omega-3 in hyperactivity, French researchers ha...fic positive effects on,impulse control., These r...
Breaking Medicine Technology:Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2Blue Cross Blue Shield Of Michigan Battles Sluggish Economy With Diverse Product Lineup 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Haughton Pitts Joins AARP Illinois Executive Council 5705 1Haughton Pitts Joins AARP Illinois Executive Council 5705 2VA Budget Earns High Praise 5700 1VA Budget Earns High Praise 5700 2The Good the Bad and the Ugly of the Nunez Perata Health Plan 5695 1The Good the Bad and the Ugly of the Nunez Perata Health Plan 5695 2Providence Hospital Study Finds Communication System Leads to Faster Heart Attack Treatment 774 1Providence Hospital Study Finds Communication System Leads to Faster Heart Attack Treatment 774 2
...ound Targeting Receptor Tyrosine Kinase EphA2 Show...cal Models -, GAITHERSBURG, Md. and CARLSBAD, Cali...mune, Inc. and Micromet, Inc. today,announced that...),molecule (bscEphA2xCD3) show that the compound k...w those required by classical,monoclonal antibody-...
...enn.--(BUSINESS WIRE)--Apr 19, 2007 - King,Pharmac...Company,has positive top-line results from the Pha...safety of the Company,s ALTACE(R),(ramipril) diure...,continuing to evaluate the trial data and expects...scientific conference., About King Pharmaceuticals...
Other Medicine Technology:MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE,Molecule 2MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE,Molecule 3MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE,Molecule 4MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE,Molecule 5King Pharmaceuticals Announces Plan to Report Positive Data from,Phase III Clinical Trial Evaluating the Combination of Altace with,Hydrochlorothiazide 2
...Tosoh, innovators of automated random access immun...atured system which builds on the proven reliabili...nced automation, optimum sensitivity, rapid result...Test Menu: Thyroid: TSH TT3 T4 FT3 FT4 T-U...
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory.
...itros ECi brings true automation and continuous ra...ng. Highly sensitive assays for thyroid, anemia, c...bone metabolism testing are currently available, w...he Vitros ECi can simultaneously process 60 access...
The Vitros 250 is a flexible system that can meet requirements in multiple environments small hospitals, backup in large hospitals, clinics and satellite locations. The Vitros 250 also features on-b
Medicine Products: